Health Catalyst, Inc. (HCAT) stock
Close on Nov 17, 2026Market cap $103.10MP/E –Yield –
Earnings
Health Catalyst's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Health Catalyst's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $56.28M | -26.3% | $0.53 | -$0.03 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | – | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026after the close | – | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | $74.68M | – | -$1.28 | $0.08 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025after the close | $76.32M | – | -$0.32 | $0.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $80.72M | – | -$0.59 | $0.04 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | – | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | – | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | – | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | – | – | -$0.23 | $0.12 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$0.35 | $0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024after the close | $75.08M | +8.6% | -$0.53 | $0.02 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $73.77M | +7.9% | -$0.39 | $0.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $73.21M | +3.7% | -$0.58 | $0.05 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $73.87M | +8.5% | -$0.60 | $0.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | $69.16M | +6.9% | -$0.66 | -$0.05 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $68.35M | +10.7% | -$0.84 | -$0.13 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $70.63M | – | -$0.62 | -$0.03 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $68.09M | – | -$0.54 | -$0.06 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022after the close | $64.72M | – | -$0.94 | -$0.19 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $61.74M | – | -$0.82 | -$0.18 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Health Catalyst's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenueGAAP | FY2026 | $246.00M – $249.00M | – | New | Nov 5, 2026 |
| Total revenueGAAP | FY2026 | $246.00M – $249.00M | $260.00M – $265.00M | Lowered | Aug 6, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $18.00M – $18.50M | – | New | Nov 5, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $18.00M – $18.50M | $30.00M – $33.00M | Lowered | Aug 6, 2026 |
Guidance vs results
The last range Health Catalyst gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $55.00M – $56.00M | $56.28M | Above range |
| Q4 FY2025 | Revenue | $73.50M | $74.68M | Above range |
| Q3 FY2025 | Revenue | $75.00M | $76.32M | Above range |
| Q2 FY2025 | Revenue | $80.50M | $80.72M | Above range |
| Q4 FY2023 | Revenue | $70.10M – $75.10M | $75.08M | Within range |
| Q3 FY2023 | Revenue | $70.20M – $74.20M | $73.77M | Within range |
| Q2 FY2023 | Revenue | $70.30M – $74.30M | $73.21M | Within range |
| Q1 FY2023 | Revenue | $70.30M – $72.30M | $73.87M | Above range |
| Q4 FY2022 | Revenue | $66.90M – $68.90M | $69.16M | Above range |
| Q3 FY2022 | Revenue | $65.30M – $68.30M | $68.35M | Above range |
| Q2 FY2022 | Revenue | $68.00M – $71.00M | $70.63M | Within range |
| Q1 FY2022 | Revenue | $64.00M – $67.00M | $68.09M | Above range |
| Q4 FY2021 | Revenue | $61.40M – $64.40M | $64.72M | Above range |
Guidance history
Every forecast Health Catalyst put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted EBITDA | FY2026 | $18.00M – $18.50M | New |
| Nov 5, 2026 | Total revenue | FY2026 | $246.00M – $249.00M | New |
| Aug 6, 2026 | Adjusted EBITDA | FY2026 | $18.00M – $18.50M | Lowered |
| Aug 6, 2026 | Adjusted EBITDA | Q3 FY2026 | $0 – $500.00K | New |
| Aug 6, 2026 | Total revenue | FY2026 | $246.00M – $249.00M | Lowered |
| Aug 6, 2026 | Total revenue | Q3 FY2026 | $55.00M – $56.00M | New |
| May 11, 2026 | Adjusted EBITDA | FY2026 | $30.00M – $33.00M | New |
| May 11, 2026 | Adjusted EBITDA | Q2 FY2026 | $9.00M – $10.00M | New |
| May 11, 2026 | Total revenue | FY2026 | $260.00M – $265.00M | New |
| May 11, 2026 | Total revenue | Q2 FY2026 | $68.00M – $70.00M | New |
| Mar 12, 2026 | Adjusted EBITDA | Q1 FY2026 | $7.00M – $8.00M | New |
| Mar 12, 2026 | Total revenue | Q1 FY2026 | $68.00M – $70.00M | New |
| Nov 10, 2025 | Adjusted EBITDA | FY2025 | $41.00M | New |
| Nov 10, 2025 | Adjusted EBITDA | Q4 FY2025 | $13.40M | New |
| Nov 10, 2025 | Total revenue | FY2025 | $310.00M | New |
| Nov 10, 2025 | Total revenue | Q4 FY2025 | $73.50M | New |
| Aug 7, 2025 | Adjusted EBITDA | Q3 FY2025 | $10.50M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $41.00M | Reaffirmed |
| Aug 7, 2025 | Total revenue | Q3 FY2025 | $75.00M | New |
| Aug 7, 2025 | Total revenue | FY2025 | $310.00M | Lowered |
| May 7, 2025 | Adjusted EBITDA | Q2 FY2025 | $8.00M | New |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $41.00M | Reaffirmed |
| May 7, 2025 | Total revenue | Q2 FY2025 | $80.50M | New |
| May 7, 2025 | Technology revenue | FY2025 | $220.00M | New |
| May 7, 2025 | Total revenue | FY2025 | $335.00M | Raised |
| Feb 26, 2025 | Adjusted EBITDA | Q1 FY2025 | $4.00M | New |
| Feb 26, 2025 | Adjusted EBITDA | FY2025 | $41.00M | New |
| Feb 26, 2025 | Total revenue | Q1 FY2025 | $79.00M | New |
| Feb 26, 2025 | Total revenue | FY2025 | $335.00M | New |
| Feb 26, 2025 | Technology revenue | FY2025 | $220.00M | Lowered |
| Nov 6, 2024 | Adjusted EBITDA | Q4 FY2024 | $6.80M – $8.80M | New |
| Nov 6, 2024 | Adjusted EBITDA | FY2024 | $25.00M – $27.00M | Raised |
| Nov 6, 2024 | Total revenue | Q4 FY2024 | $78.00M – $84.00M | New |
| Nov 6, 2024 | Total revenue | FY2024 | $305.00M – $311.00M | Narrowed |
| Aug 7, 2024 | Adjusted EBITDA | Q3 FY2024 | $6.00M – $8.00M | New |
| Aug 7, 2024 | Adjusted EBITDA | FY2024 | $24.00M – $26.00M | Reaffirmed |
| Aug 7, 2024 | Total revenue | Q3 FY2024 | $74.50M – $77.50M | New |
| Aug 7, 2024 | Total revenue | FY2024 | $304.00M – $312.00M | Reaffirmed |
| May 9, 2024 | Adjusted EBITDA | Q2 FY2024 | $5.00M – $7.00M | New |
| May 9, 2024 | Adjusted EBITDA | FY2024 | $24.00M – $26.00M | Reaffirmed |
| May 9, 2024 | Total revenue | Q2 FY2024 | $73.50M – $76.50M | New |
| May 9, 2024 | Total revenue | FY2024 | $304.00M – $312.00M | Reaffirmed |
| Feb 22, 2024 | Adjusted EBITDA | Q1 FY2024 | $2.00M – $4.00M | New |
| Feb 22, 2024 | Adjusted EBITDA | FY2024 | $24.00M – $26.00M | New |
| Feb 22, 2024 | Total revenue | Q1 FY2024 | $72.50M – $76.50M | New |
| Feb 22, 2024 | Total revenue | FY2024 | $304.00M – $312.00M | New |
| Nov 2, 2023 | Adjusted EBITDA | Q4 FY2023 | $300.00K – $2.30M | Reaffirmed |
| Nov 2, 2023 | Adjusted EBITDA | FY2023 | $10.00M – $12.00M | Reaffirmed |
| Nov 2, 2023 | Total revenue | Q4 FY2023 | $70.10M – $75.10M | Reaffirmed |
| Nov 2, 2023 | Total revenue | FY2023 | $291.00M – $296.00M | Reaffirmed |
| Oct 27, 2023 | Adjusted EBITDA | Q4 FY2023 | $300.00K – $2.30M | New |
| Oct 27, 2023 | Adjusted EBITDA | FY2023 | $10.00M – $12.00M | Reaffirmed |
| Oct 27, 2023 | Total revenue | Q4 FY2023 | $70.10M – $75.10M | New |
| Oct 27, 2023 | Total revenue | FY2023 | $291.00M – $296.00M | Raised |
| Aug 8, 2023 | Adjusted EBITDA | Q3 FY2023 | $0 – $2.50M | New |
| Aug 8, 2023 | Adjusted EBITDA | FY2023 | $10.00M – $12.00M | Raised |
| Aug 8, 2023 | Total revenue | Q3 FY2023 | $70.20M – $74.20M | New |
| Aug 8, 2023 | Total revenue | FY2023 | $290.50M – $295.50M | Raised |
| May 9, 2023 | Adjusted EBITDA | Q2 FY2023 | $750.00K – $4.75M | New |
| May 9, 2023 | Adjusted EBITDA | FY2023 | $9.00M – $11.00M | Reaffirmed |
| May 9, 2023 | Total revenue | Q2 FY2023 | $70.30M – $74.30M | New |
| May 9, 2023 | Total revenue | FY2023 | $290.00M – $295.00M | Reaffirmed |
| Feb 28, 2023 | Adjusted EBITDA | Q1 FY2023 | $1.00M – $2.50M | New |
| Feb 28, 2023 | Adjusted EBITDA | FY2023 | $9.00M – $11.00M | New |
| Feb 28, 2023 | Total revenue | Q1 FY2023 | $70.30M – $72.30M | New |
| Feb 28, 2023 | Total revenue | FY2023 | $290.00M – $295.00M | New |
| Nov 8, 2022 | Adjusted EBITDA | Q4 FY2022 | -$2.10M – -$100.00K | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | -$4.00M – -$2.00M | Raised |
| Nov 8, 2022 | Total revenue | Q4 FY2022 | $66.90M – $68.90M | New |
| Nov 8, 2022 | Total revenue | FY2022 | $274.00M – $276.00M | Raised |
| Aug 4, 2022 | Adjusted EBITDA | Q3 FY2022 | -$6.00M – -$4.00M | New |
| Aug 4, 2022 | Adjusted EBITDA | FY2022 | -$6.00M – -$4.00M | Lowered |
| Aug 4, 2022 | Total revenue | Q3 FY2022 | $65.30M – $68.30M | New |
| Aug 4, 2022 | Total revenue | FY2022 | $271.50M – $275.50M | Lowered |
| May 10, 2022 | Adjusted EBITDA | Q2 FY2022 | -$1.50M – $500.00K | New |
| May 10, 2022 | Adjusted EBITDA | FY2022 | -$4.00M – -$2.00M | Reaffirmed |
| May 10, 2022 | Total revenue | Q2 FY2022 | $68.00M – $71.00M | New |
| May 10, 2022 | Total revenue | FY2022 | $287.80M – $292.80M | Reaffirmed |
| Mar 1, 2022 | Adjusted EBITDA | Q1 FY2022 | -$2.50M – -$500.00K | New |
| Mar 1, 2022 | Adjusted EBITDA | FY2022 | -$4.00M – -$2.00M | New |
| Mar 1, 2022 | Total revenue | Q1 FY2022 | $64.00M – $67.00M | New |
| Mar 1, 2022 | Total revenue | FY2022 | $287.80M – $292.80M | New |
| Nov 9, 2021 | Adjusted EBITDA | Q4 FY2021 | -$7.50M – -$5.50M | New |
| Nov 9, 2021 | Adjusted EBITDA | FY2021 | -$12.50M – -$10.50M | New |
| Nov 9, 2021 | Total revenue | Q4 FY2021 | $61.40M – $64.40M | New |
| Nov 9, 2021 | Total revenue | FY2021 | $238.60M – $241.60M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Health Catalyst filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?